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Abstract Transforming growth factor-L (TGF-L) plays a
pivotal role in the extracellular matrix accumulation observed
in chronic progressive tissue fibrosis, but the intracellular
signaling mechanism by which TGF-L stimulates this process
remains poorly understood. We examined whether mitogen-
activated protein kinase (MAPK) routes were involved in TGF-
L1-induced collagen expression in L6E9 myoblasts. TGF-L1
induced p38 and extracellular signal-regulated kinase (ERK) 1/2
phosphorylation whereas no effect on Jun N-terminal kinase
phosphorylation was observed. Biochemical blockade of p38 but
not of the ERK MAPK pathway abolished TGF-L1-induced
K2(I) collagen mRNA expression and accumulation. These data
indicate that TGF-L1-induced p38 activation is involved in TGF-
L1-stimulated collagen synthesis. ß 2002 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Transforming growth factor-L1 (TGF-L1) is a member of a
large family of polypeptide factors that participates in a wide
array of biological activities such as development and wound
repair, as well as pathological processes [1^3]. TGF-L1 plays a
pivotal role in the extracellular matrix accumulation observed
in chronic progressive tissue ¢brosis [2,4] and in the patho-
genesis of several chronic in£ammatory diseases including pul-
monary ¢brosis [5], glomerulonephritis [6] and proliferative
vitreoretinopathy [7]. Each of these diseases is characterized
by increased expression of TGF-L1 and excessive accumula-
tion of extracellular matrix (ECM). TGF-L1 induces the syn-
thesis of a number of ECM proteins in vivo and in vitro,
including types I and III collagen, ¢bronectin, laminin, and
proteoglycans [8^12]. Type I collagen is a major structural
component of the ECM, which is synthesized by ¢broblasts
and vascular smooth muscle cells.
Biological actions of TGF-L are mediated by two trans-
membrane Ser/Thr kinases, types I and II TGF-L receptors
[3,13], which are co-expressed by most cells, including L6E9
myoblasts [14,15]. Several studies suggest that TGF-L1 may
act as a physiological regulator of myogenic di¡erentiation in
L6E9 myoblasts. Thus, it can act as an inducer of myogenic
di¡erentiation in mitogen-rich environments [16], although in
the absence of mitogens, TGF-L1 acts as an inhibitor of my-
oblast di¡erentiation [17]. This inhibition seems to be medi-
ated by TGF-L1-induced upregulation of type I collagen ex-
pression and deposition in L6E9 myoblasts, because a ¢brillar
type I collagen layer inhibits L6E9 myoblast di¡erentiation
[17]. Ignotz et al. [9] have demonstrated in rat L6E9 myoblasts
that TGF-L1 induces collagen and ¢bronectin synthesis.
The routes that participate in this myogenic response to
TGF-L1 are still unknown. TGF-L1 has been shown to acti-
vate the Smad cascade, leading to the regulation of speci¢c
genes. In addition, the mitogen-activated protein kinase
(MAPK) routes have also been implicated in signal transduc-
tion by TGF-L receptors. However, to which extent the later
routes may participate in collagen deposition triggered by
TGF-L1 in L6E9 cells is unresolved. This investigation was
thus undertaken to determine whether TGF-L1 activates spe-
ci¢c MAPK signaling pathway(s) in cultured rat L6E9 myo-
blasts and whether this MAPK activation mediates the bio-
logical e¡ect of TGF-L1 on type I collagen synthesis and
accumulation. Our ¢ndings clearly show that TGF-L1 acti-
vates extracellular signal-regulated kinase (ERK) 1/2 and
p38 MAPK pathways, and that p38 MAPK activation is in-
volved in TGF-L1-induced collagen synthesis.
2. Materials and methods
2.1. Cell culture and growth factor stimulation
L6E9 rat myoblasts were seeded at a density of 4U105 cells/plate on
100 mm petri dishes for Northern and Western blot analysis and at
2U104 cells/well on 24 well plates for ECM measurements. Cells were
grown in Dulbecco’s modi¢ed Eagle’s medium (Gibco) containing
10% fetal bovine serum (Biowhittaker) and 100 U/ml of penicillin/
streptomycin at 37‡C in the presence of 5% CO2. When cultures
achieved 80^90% con£uence, cells were serum-starved for 24 h. Cells
were treated with active human recombinant TGF-L1 (RpD Systems)
or control vehicle during 24 h in the absence of serum.
Inhibitors used in these experiments included the MEK-1 inhibitor
PD98059 (50 WM) (New England Biolabs), and the p38 MAPK in-
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hibitor, SB203580 (10 WM) (Calbiochem). Pretreatments with these
inhibitors were for 30 min.
2.2. Collagen determination
The collagen content in the medium was quanti¢ed by measuring
the incorporation of [3H]proline into collagen proteins, as previously
described [18]. Protein content of cell extracts was determined by the
Bradford assay (Bio-Rad).
2.3. Northern blot analysis
Total RNA was isolated by cell lysis with the guanidinium thiocya-
nate^phenol^chloroform method [19]. A 20 Wg aliquot of total RNA
was electrophoresed in 1.2% denaturing formaldehyde agarose gel and
blotted onto Hybond-N (Amersham). The radiolabeled probes were
hybridized at 60‡C in a hybridization solution (1% (w/v) SDS, 10%
(w/v) dextran sulfate, 1 M NaCl). Blots were washed twice in 3 M
NaCl, 30 mM sodium citrate (pH 7.0), 1% (w/v) SDS for 30 min each
at 60‡C followed by a last wash with 0.3 M NaCl, 3 mM sodium
citrate (pH 7.0), 0.1% (w/v) SDS for 1 h at room temperature. The rat
pro-K2(I) collagen (600 bp PstI fragment) cDNA probe was obtained
by digestion of the corresponding cDNA inserted into plasmid
pUC18, and was kindly provided by Dr. Diego Rodr|¤guez-Puyol
(University of Alcala¤ de Henares, Madrid, Spain). To control for
relative equivalence of RNA loading, blots were hybridized with
32P-labeled 18S rRNA probe.
2.4. Cell lysates and Western blot analysis
Myoblasts were treated with 50 pM TGF-L1 for di¡erent periods of
time leading up to simultaneous harvest. Total cell extracts were ob-
tained by cell lysis in RIPA bu¡er (50 mM Tris^HCl (pH 7.5), 150
mM NaCl, 1% (v/v) Nonidet P-40, 0.1% (w/v) SDS) containing pro-
tease and phosphatase inhibitors (1 mM phenylmethylsulfonyl £uo-
ride, 1 mM ethylenediaminetetraacetic acid, 1 Wg/ml leupeptin, 1 Wg/
ml pepstatin, 1 Wg/ml aprotinin, 1 mM Na3VO4). Cell extracts were
then centrifuged at 15 000Ug for 10 min at 4‡C, supernatants col-
lected and protein content determined as above. Fresh cell extracts
were prepared in Laemmli bu¡er (¢nal concentration: 125 mM Tris^
HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 0.1% (w/v) bromo-
phenol blue, 1% (v/v) 2-mercaptoethanol). Samples were resolved by
SDS^PAGE and then electroblotted onto Immobilon-P polyvinyli-
dene di£uoride membranes. The membranes were incubated with
anti-ERK2 antibody C-14, 0.04 Wg/ml; anti-phospho-ERK antibody,
E-4, 0.02 Wg/ml; anti-phospho p38, 0.2 Wg/ml; anti-p38 1 Wg/ml, or
anti-Jun N-terminal kinase (JNK) antibody, C-17 (Santa Cruz) for 2 h
at room temperature followed by incubation with the corresponding
secondary antibody conjugated with horseradish peroxidase for 30
min at room temperature. Signal development was by chemilumines-
cence. The levels of activated MAPK were quantitated by densitomet-
ric analysis using the National Institutes of Health (NIH) image pro-
gram. Results shown were corrected for total MAPK.
Immunoprecipitation of JNK was performed by binding 2 Wg of
JNK polyclonal antibody C-17 (Santa Cruz) with 60 Wl protein A
Sepharose beads and 1 mg of protein from whole cell extracts. Im-
munoprecipitates were eluted by boiling in 2USDS Laemmli bu¡er
prior to 10% SDS^PAGE. The membranes were incubated with the
anti-p-JNK G-7 (Santa Cruz) antibody. Western analysis and auto-
radiographic detection were performed as above.
3. Results
3.1. Stimulation of pro-K2(I) collagen mRNA expression and
collagen accumulation by TGF-L1
Treatment with exogenous TGF-L1 increased pro-K2(I) col-
lagen mRNA expression in a dose-dependent fashion (Fig.
1A). To assess that increased collagen mRNA expression
was followed by collagen deposition, we measured [3H]proline
incorporation into collagen proteins. Similarly to the mRNA
data, exogenous TGF-L1 increased collagen accumulation in
the culture media of L6E9 myoblasts in a dose-dependent
fashion (Fig. 1B).
3.2. Activation of p38 and ERK1/2 in L6E9 myoblasts
by TGF-L1
Previous reports have suggested that some of the biological
actions of TGF-L1 are mediated by activation of MAPK sig-
Fig. 1. E¡ect of TGF-L1 on induction of pro-K2(I) collagen mRNA
expression and accumulation in L6E9 rat myoblasts. Cultured L6E9
myoblasts were incubated with increasing concentrations of TGF-L1
for 24h. A: Total RNA was extracted and isolated for Northern
analyses where pro-K2(I) collagen mRNA appeared at 5.2 kb. The
autoradiograms were analyzed by optical scanning densitometry and
values are expressed as arbitrary units with normalization of the re-
sults according to the corresponding transcripts levels for the ribo-
somal 18S gene. Figure shows a representative experiment of three
performed in the same conditions. B: Metabolic radiolabeling with
[3H]proline was carried out for 24 h. Collagen accumulation was
measured according to the amount of radioactivity incorporated
into the protein fraction of the medium. Each value represents the
mean þ S.E.M. of three experiments, each in triplicate. *P6 0.001
versus basal; P6 0.001 versus TGF-L1 (5 pM); #P6 0.001 versus
TGF-L1 (50 pM).
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Fig. 2. MAPK pathway activation by TGF-L1. L6E9 rat myoblasts were incubated with exogenous TGF-L1 (50 pM) for the times indicated.
The ¢gure shows a representative experiment of three performed in the same conditions. A: Phosphorylation of p38 MAPK from cellular ex-
tracts was determined using Western blot with anti-phospho-p38 antibody (phospho-p38). Western blot of total p38 protein (total p38) in cellu-
lar extracts is also shown. Cell extracts from L6E9 myoblasts stimulated by osmotic shock (0.7 M sorbitol, 60 min) served as a positive control
(C+). Bar graphs shown the levels of activated p38 corrected for total p38. B: Phosphorylation of p38 MAPK from cells treated with TGF-L1
for 24 h. Western blot of total p38 protein (total p38) in cellular extracts is also shown. Cell extracts from L6E9 myoblasts stimulated by os-
motic shock (0.7 M sorbitol, 60 min) were used as a positive control (C+). C: Phosphorylation of ERK1/2 MAPK from cellular extracts was
determined using Western blot with phospho-p44/42 MAPK antibody (phospho-ERK1/2). Western blot of total ERK1/2 protein (total ERK1/
2) in cellular extracts is also shown. Bar graphs shown the levels of activated ERK1/2 corrected for total ERK1/2.
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naling pathways [20,21]. To investigate the potential inter-
mediate role of MAPKs on TGF-L1-induced accumulation
of K2(I) collagen, we analyzed the e¡ect of this factor on
collagen deposition, as well as on the phosphorylation status
of MAPK. This latter study was carried out using antibodies
that speci¢cally recognize the phosphorylated form of these
MAPKs. In addition, we assessed the e¡ect of inhibiting the
di¡erent MAPK routes on TGF-L1-induced collagen deposi-
tion.
As shown in Fig. 2A, exogenous TGF-L1 (50 pM) increased
the phosphorylation of p38 MAPK at 30 min of stimulation
and p38 remains phosphorylated at least 24 h (Fig. 2B). The
amount of the total p38 MAPK remained unchanged during
the experiment, as indicated by Western blotting of the lysates
Fig. 3. Inhibition of the p38 MAPK pathway with SB203580 blocks TGF-L1-induced pro-K2(I) collagen mRNA expression and collagen accu-
mulation. L6E9 rat myoblasts were pretreated with (+) or without (3) SB203580 (10 WM) and incubated in the presence (+) or absence (3) of
exogenous TGF-L1 (50 pM) for 24 h. A: Northern analyses of pro-K2(I) collagen mRNA as in Fig. 1A. B: Collagen accumulation was mea-
sured as in Fig. 1B. Each value represents the mean þ S.E.M. of two experiments, each in triplicate. *P6 0.001 versus basal; #P6 0.001 versus
TGF-L1 (50 pM). SB203580 was dissolved in DMSO (0.2%). Cells treated with the SB203580 solvent (DMSO) are also shown.
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using antibodies that detect total (phosphorylation state-inde-
pendent) p38 protein. As a positive control, L6E9 cell lysates
stimulated by osmotic shock (0.7 M sorbitol, 1 h) were ana-
lyzed in the same gels. Osmotic shock strongly activated p38
phosphorylation to levels higher than those induced by 50 pM
TGF-L1.
To determine whether TGF-L1 activated the ERK1/ERK2
MAPK pathway in cultured L6E9 myoblasts, we performed
Western blot analyses using an anti-phospho-p44/42 MAPK
monoclonal antibody. ERK1 and ERK2 phosphorylation in-
creased slightly as early as 5 min after stimulation with exog-
enous TGF-L1 and persisted for as long as 60 min, declining
thereafter. No changes in total ERK1/2 proteins were ob-
served when blots were probed with antibodies that detect
the total ERK1/2 proteins (Fig. 2C).
We also analyzed whether TGF-L1 activated the SAPK/
JNK pathway in cultured rat L6E9 myoblasts. In contrast to
the p38 and ERK1/ERK2 MAPKs, there were no signi¢cant
increases in the phosphorylation of SAPK/JNK MAPK upon
TGF-L1 treatment (data not shown). As a positive control,
UV irradiation strongly stimulated JNK phosphorylation.
3.3. Inhibition of TGF-L1 K2(I) collagen mRNA expression by
p38 MAPK but not by ERK1/2 inhibition
Preincubation of L6E9 myoblasts with SB203580, a speci¢c
inhibitor of p38 MAPK, e⁄ciently prevented TGF-L1-in-
duced K2(I) collagen mRNA expression (Fig. 3A). In addition,
SB203580 also inhibited TGF-L1-induced collagen accumula-
tion (Fig. 3B). In addition, PD98059, an ERK1/2 MAPK
route inhibitor, prevented the activation of the ERK1/ERK2
MAPK pathway (Fig. 4), but failed to inhibit TGF-L1-in-
duced K2(I) collagen mRNA expression (Fig. 5A) and total
collagen accumulation (Fig. 5B).
4. Discussion
This study examined the role of the MAPK signaling cas-
cades in mediating the e¡ect of TGF-L1 in collagen synthesis
in rat L6E9 myoblasts. Treatment of L6E9 myoblasts with
exogenous TGF-L1 resulted in p38 and ERK1/ERK2 phos-
phorylation. Thus, our ¢ndings demonstrate for the ¢rst time
a rapid activation of p38 and ERK1/ERK2 MAPK in rat
L6E9 myoblasts, occurring within 5^30 min of TGF-L1 addi-
tion. It is interesting to note that p38 MAPK remains acti-
vated for at least 24 h. However, no apparent activation of
JNK was observed within the same time periods of TGF-L1
treatment. JNK and p38 MAPKs are strongly activated by
environmental stresses and in£ammatory cytokines, and are
inconsistently activated by insulin and growth factors [22]. In
almost all instances, the same stimuli that recruit JNKs also
recruit p38 MAPK [23]. However, in the present study we
found a dissociation between JNK and p38 activities as
TGF-L1 treatment activated p38 but not JNK. This is com-
patible with the failure of a rapid JNK activation by TGF-L1
also observed in studies by Chin et al. [21] in mesangial cells.
With respect to the roles of MAPKs in myoblasts, Jones et
al. [24] demonstrated that ¢broblast growth factor-stimulated
ERK1/2 signaling is required during the G1 phase of the cell
cycle for commitment of DNA synthesis, but is not required
for mitosis once cells have entered the S-phase. Moreover,
ERK1/2 signaling is not required either to repress di¡erentia-
tion, to promote skeletal muscle gene expression, or to pro-
Fig. 4. Inhibition of the ERK1/2 pathway with PD98059 blocks TGF-L1-induced ERK activation. Representative blot of phosphorylation of
ERK from cellular extracts determined using Western blot with anti-phospho-ERK antibody (phospho ERK1/2). Western blot of total ERK1/2
protein (total ERK1/2) in cellular extracts is also shown. Where indicated, cells were incubated with TGF-L1 (50 pM) and PD98059 (10 WM)
for 24 h. Cell extracts from L6E9 myoblasts stimulated by osmotic shock (0.7 M sorbitol, 60 min) served as a positive control (C+). Bar graphs
shown the levels of activated ERK1/2 corrected for total ERK1/2.
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mote myoblast fusion. In addition, activation of the insulin-
like growth factor (IGF) autocrine loop is required for myo-
genic di¡erentiation leading to a sustained activation of phos-
phoinositide 3P-kinase (PI3-kinase) [25,26], p38 [26] and
ERK1/ERK2 [27]. Furthermore, these authors demonstrated
that blocking the Raf/MEK/ERK cascade with PD98059 does
not block myogenic di¡erentiation; however, myotubes do
not form. Thus, PI3-kinase, in association with IRS-1, is in-
volved in an ERK-independent signaling pathway in myo-
blasts required for IGF-dependent myogenic di¡erentiation
and in inducing sustained activation of ERKs necessary for
later stages of di¡erentiation. In addition, recent studies dem-
onstrated that phosphorylation by p38 induced transcriptional
activity of myocyte enhancer factor 2 [28], which plays a piv-
otal role in muscle gene transcription and di¡erentiation of
skeletal myoblasts [29]. Thus, MAPKs seem to play a major
role in regulating myoblast proliferation and di¡erentiation.
In the present study, we also evaluated the e¡ect of inhibit-
ing the ERK1/ERK2 or the p38 MAPK pathways on collagen
synthesis. Blockade of the ERK cascade by PD98059, a spe-
ci¢c inhibitor of MEK1 that prevents downstream activation
of ERK1/ERK2, did not prevent induction by TGF-L1 of
K2(I) collagen mRNA or collagen I accumulation in L6E9
myoblasts. By contrast, in the presence of SB203580, a speci¢c
inhibitor of the p38 MAPK cascade, exogenous TGF-L1 was
unable to induce both K2(I) collagen mRNA and collagen I
accumulation in L6E9 myoblasts. Our present data demon-
strate that p38 MAPK activation mediates TGF-L1-induced
collagen I synthesis in L6E9 myoblasts. These data are in
agreement with those of Hanafusa et al. [30] demonstrating
the involvement of the p38 MAPK pathway in TGF-L1-in-
duced gene expression. In addition, Chin et al. [21] have re-
cently reported that in rat mesangial cells, TGF-L1 rapidly
induced ERK1/ERK2 activation, p38 phosphorylation and
pro-K1(I) collagen mRNA expression. Their ¢ndings suggest
that the p38 MAPK pathway functions as a component in the
signaling of pro-K1(I) collagen induction by TGF-L1 in me-
sangial cells, which is in agreement with the results of the
present study. Also very recently, it has been demonstrated
that p38 MAPK mediates the TGF-L1-induced expression of
human collagenase-3 (MMP-13) by fetal skin ¢broblasts [31].
In summary, our results demonstrate that TGF-L1 activates
di¡erent MAPK routes in L6E9 myoblasts and support the
involvement of the p38 MAPK pathway in TGF-L1-induced
collagen synthesis and accumulation in L6E9 myoblasts. The
activation of multiple pathways may account for the pleiotro-
pic actions of TGF-L1 in these cells.
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